1.Survey and analysis on the incidence of neck and back pain among aviators
Peipei HUANG ; Xueyu HU ; Xiaobing WANG ; Huaizhang YANG ; Zuojie ZHAO ; Zhe WANG ; Zuojing LUO
Journal of Navy Medicine 2016;37(2):103-105,138
Objective To investigate the incidence and risk factors of neck and back pain in pilots, aviation cadets and me-chanical maintenance personnel, with an aim to prevent the occurrence of the disorder among them.Methods A survey of 2001 cases of medical data was conducted, and then, the derived data concerning neck and back pain were compared and analyzed between pilots, aviation cadets and mechanical maintenance personnel.Results The incidence of neck and back pain in aviation cadets was 19.3%, and the incidence rates of the same disorder in pilots and mechanical maintenance personnel were 43.0%and 31.9%respectively.The incidence of neck and back pain in the aviation cadets flying fighters was 29%, and the incidence rates of the same disorder in the avia-tion cadets flying transports and helicopters were 44.1%and 37.4% respectively.Risk factors of neck and back pain among aviation cadets included age, flying time, smoking history, body mass index and lumbodorsal muscular exercise.Conclusion The incidence of neck and back pain in pilots was significantly higher than that in aviation cadets and mechanical maintenance personnel, and the inci-dence of the disorder was also relatively high in pilots flying transports.Flying time was the most important risk factor of neck and back pain, and the survey revealed that lumbodorsal muscular exercise was an effective protective factor.Close attention should be paid to the prevention of neck and back pain and counter measures should be developed for effective prevention of the disorder.
2.Hypertension and angina pectoris caused by sorafenib
Xinfeng ZHANG ; Cuixia QIAO ; Xufeng CHENG ; Huaizhang WANG ; Xuchu YANG ; Qilong GAO
Adverse Drug Reactions Journal 2015;(6):457-459
A 57-year-old male patient received oral sorafenib 400 mg twice daily for pulmonary metastases after operation of thyroid carcinoma. About 3 and a half months of treatment,the patient experienced dizziness,pain in the anterior region of the heart and blood pressure of 180 / 105 mmHg(before treatment it was 120 / 75 mmHg). He received oral metoprolol administration(initial dose of 25 mg twice daily,gradually increased to 200 mg twice daily). About one and a half months later,he received sustained release capsules of isosorbide mononitrate 50 mg once daily because of the intermittent attack of precordial pain. Angina pectoris still occurred frequently. He underwent percutaneous coronary intervention twice(a total of 2 stents implantation). Hypertension and angina pectoris were still poorly controlled. On month 19 of sorafenib treatment,the dose of drug was reduced to 400 mg once daily. His blood pressure was 135 / 85 mmHg but angina still occurred intermittently. On month 22,sorafenib was stopped. Two months later,the patient's blood pressure declined to 130 / 80 mmHg,and the frequency of angina pectoris decreased. Four months after the termination of sorafenib,his blood pressure was 120 / 75 mmHg and no episode of angina pectoris occurred.
3.Hypertension and angina pectoris caused by sorafenib
Xinfeng ZHANG ; Cuixia QIAO ; Xufeng CHENG ; Huaizhang WANG ; Xuchu YANG ; Qilong GAO
Adverse Drug Reactions Journal 2015;(6):457-459
A 57-year-old male patient received oral sorafenib 400 mg twice daily for pulmonary metastases after operation of thyroid carcinoma. About 3 and a half months of treatment,the patient experienced dizziness,pain in the anterior region of the heart and blood pressure of 180 / 105 mmHg(before treatment it was 120 / 75 mmHg). He received oral metoprolol administration(initial dose of 25 mg twice daily,gradually increased to 200 mg twice daily). About one and a half months later,he received sustained release capsules of isosorbide mononitrate 50 mg once daily because of the intermittent attack of precordial pain. Angina pectoris still occurred frequently. He underwent percutaneous coronary intervention twice(a total of 2 stents implantation). Hypertension and angina pectoris were still poorly controlled. On month 19 of sorafenib treatment,the dose of drug was reduced to 400 mg once daily. His blood pressure was 135 / 85 mmHg but angina still occurred intermittently. On month 22,sorafenib was stopped. Two months later,the patient's blood pressure declined to 130 / 80 mmHg,and the frequency of angina pectoris decreased. Four months after the termination of sorafenib,his blood pressure was 120 / 75 mmHg and no episode of angina pectoris occurred.

Result Analysis
Print
Save
E-mail